Fisher & Paykel Healthcare Corporation Limited · NZX:FPH
Fisher & Paykel Healthcare — Shareholder Meeting (2010)
6 slides from Fisher & Paykel Healthcare's shareholder meeting presentation, 2010
Slide 1: Consistent Growth Strategy
Consistent Growth Strategy US $ Millions Operating Revenue 341.5 299.3 • Innovative devices which 271.5 improve care and outcomes 229.1 • Increase value per patient • New patient groups • International expansion 2007 2008 2009 2010 1
Slide 2: Financial Highlights / Revenue by Product Group
Financial Highlights • Operating revenue NZ$503.3M + 10% US$341.5M + 14% • Net profit NZ$71.6M + 15% • Operating margin 20.4% • R&D investment 7.0% of revenue 2 Revenue by Product Group Distributed/ Other 5% Respiratory OSA & Acute 47% 48% ¯ Consumable and accessory Operating revenue products repres
Slide 3: Revenue by Region
Revenue by Region Asia Pacific/ Other 21% North America 47% Europe 32% Operating revenue 12 months to 31 March 2010 4 Respiratory & Acute Care 5
Slide 4: Expansion Opportunities / Obstructive Sleep Apnea
Expansion Opportunities Surgical Invasive Non-invasive Nasal High Ventilation Ventilation Flow Oxygen Humidity Therapy AIRVOTM 6 Obstructive Sleep Apnea 7
Slide 5: Research & Development
ICON Introduced Novo Auto Premo 8 Research & Development • NZ$35M R&D investment +25% • New product pipeline includes: – Humidifier systems – Respiratory consumables – Masks – Compliance monitoring technologies 9
Slide 6: Investment for Growth / Outlook
Investment for Growth • NZ$50M capex NZ • NZ$7M capex Mexico 10 Outlook First Half • Operating revenue – NZ$245 million approx. • Profit after tax – NZ$27 million approx. Full Year • Profit after tax – NZ$65-70 million approx. (if average for remainder of year NZD:USD =0.70) 11
Fisher & Paykel Healthcare — Shareholder Meeting (2010) on 6ix